

Viral Vectors and Plasmid DNA Manufacturing Industry Research Report 2024

<https://marketpublishers.com/r/VDC1C55AB35CEN.html>

Date: April 2024

Pages: 134

Price: US\$ 2,950.00 (Single User License)

ID: VDC1C55AB35CEN

Abstracts

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.

According to APO Research, The global Viral Vectors and Plasmid DNA Manufacturing market was valued at US\$ million in 2023 and is anticipated to reach US\$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.

North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.

In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Viral Vectors and Plasmid DNA Manufacturing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors and Plasmid DNA Manufacturing.

The Viral Vectors and Plasmid DNA Manufacturing market size, estimations, and forecasts are provided in terms of revenue (\$ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors and Plasmid DNA Manufacturing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

BioReliance

Cobra Biologics

Oxford BioMedica

UniQure

FinVector

MolMed

MassBiologics

Richter-Helm

FUJIFILM Diosynth Biotechnologies

Lonza

Aldevron

Eurogentec

Cell and Gene Therapy Catapult

Biovian

Thermo Fisher Scientific (Brammer Bio)

VGXI

PlasmidFactory

Viral Vectors and Plasmid DNA Manufacturing segment by Type

Plasmid DNA

Viral Vectors

Viral Vectors and Plasmid DNA Manufacturing Segment by Application

Cancers

Inherited Disorders

Viral Infections

Others

Viral Vectors and Plasmid DNA Manufacturing Segment by Region

North America

United States

Canada

Europe

Germany

France

UK

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vectors and Plasmid DNA Manufacturing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vectors and Plasmid DNA Manufacturing and provides them with information on

key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vectors and Plasmid DNA Manufacturing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced

by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Viral Vectors and Plasmid DNA Manufacturing companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

Chapter 13: The main points and conclusions of the report.

Contents

1 PREFACE

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 MARKET OVERVIEW

- 2.1 Product Definition
- 2.2 Viral Vectors and Plasmid DNA Manufacturing by Type
 - 2.2.1 Market Value Comparison by Type (2019 VS 2023 VS 2030)
 - 2.2.2 Plasmid DNA
 - 2.2.3 Viral Vectors
- 2.3 Viral Vectors and Plasmid DNA Manufacturing by Application
 - 2.3.1 Market Value Comparison by Application (2019 VS 2023 VS 2030)
 - 2.3.2 Cancers
 - 2.3.3 Inherited Disorders
 - 2.3.4 Viral Infections
 - 2.3.5 Others
- 2.4 Assumptions and Limitations

3 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY TYPE

- 3.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Type (2019-2024)
- 3.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Type (2025-2030)

4 VIRAL VECTORS AND PLASMID DNA MANUFACTURING BREAKDOWN DATA BY APPLICATION

- 4.1 Global Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by

Application (2019-2024)

4.2 Global Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Application (2019-2024)

5 GLOBAL GROWTH TRENDS

5.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Perspective (2019-2030)

5.2 Global Viral Vectors and Plasmid DNA Manufacturing Growth Trends by Region

5.2.1 Global Viral Vectors and Plasmid DNA Manufacturing Market Size by Region: 2019 VS 2023 VS 2030

5.2.2 Viral Vectors and Plasmid DNA Manufacturing Historic Market Size by Region (2019-2024)

5.2.3 Viral Vectors and Plasmid DNA Manufacturing Forecasted Market Size by Region (2025-2030)

5.3 Viral Vectors and Plasmid DNA Manufacturing Market Dynamics

5.3.1 Viral Vectors and Plasmid DNA Manufacturing Industry Trends

5.3.2 Viral Vectors and Plasmid DNA Manufacturing Market Drivers

5.3.3 Viral Vectors and Plasmid DNA Manufacturing Market Challenges

5.3.4 Viral Vectors and Plasmid DNA Manufacturing Market Restraints

6 MARKET COMPETITIVE LANDSCAPE BY PLAYERS

6.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue

6.1.1 Global Top Viral Vectors and Plasmid DNA Manufacturing Players by Revenue (2019-2024)

6.1.2 Global Viral Vectors and Plasmid DNA Manufacturing Revenue Market Share by Players (2019-2024)

6.2 Global Viral Vectors and Plasmid DNA Manufacturing Industry Players Ranking, 2022 VS 2023 VS 2024

6.3 Global Key Players of Viral Vectors and Plasmid DNA Manufacturing Head office and Area Served

6.4 Global Viral Vectors and Plasmid DNA Manufacturing Players, Product Type & Application

6.5 Global Viral Vectors and Plasmid DNA Manufacturing Players, Date of Enter into This Industry

6.6 Global Viral Vectors and Plasmid DNA Manufacturing Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 NORTH AMERICA

7.1 North America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)

7.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)

7.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)

7.5 United States

7.6 Canada

8 EUROPE

8.1 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)

8.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)

8.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Russia

8.10 Nordic Countries

9 ASIA-PACIFIC

9.1 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)

9.2 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)

9.4 Asia-Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)

9.5 China

- 9.6 Japan
- 9.7 South Korea
- 9.8 Southeast Asia
- 9.9 India
- 9.10 Australia

10 LATIN AMERICA

- 10.1 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
- 10.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 10.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
- 10.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
- 10.5 Mexico
- 10.6 Brazil

11 MIDDLE EAST & AFRICA

- 11.1 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size (2019-2030)
- 11.2 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Growth Rate by Country: 2019 VS 2023 VS 2030
- 11.3 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2019-2024)
- 11.4 Middle East & Africa Viral Vectors and Plasmid DNA Manufacturing Market Size by Country (2025-2030)
- 11.5 Turkey
- 11.6 Saudi Arabia
- 11.7 UAE

12 PLAYERS PROFILED

- 12.1 BioReliance
 - 12.1.1 BioReliance Company Information
 - 12.1.2 BioReliance Business Overview
 - 12.1.3 BioReliance Revenue in Viral Vectors and Plasmid DNA Manufacturing

Business (2019-2024)

12.1.4 BioReliance Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

12.1.5 BioReliance Recent Developments

12.2 Cobra Biologics

12.2.1 Cobra Biologics Company Information

12.2.2 Cobra Biologics Business Overview

12.2.3 Cobra Biologics Revenue in Viral Vectors and Plasmid DNA Manufacturing

Business (2019-2024)

12.2.4 Cobra Biologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

12.2.5 Cobra Biologics Recent Developments

12.3 Oxford BioMedica

12.3.1 Oxford BioMedica Company Information

12.3.2 Oxford BioMedica Business Overview

12.3.3 Oxford BioMedica Revenue in Viral Vectors and Plasmid DNA Manufacturing

Business (2019-2024)

12.3.4 Oxford BioMedica Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

12.3.5 Oxford BioMedica Recent Developments

12.4 UniQure

12.4.1 UniQure Company Information

12.4.2 UniQure Business Overview

12.4.3 UniQure Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)

12.4.4 UniQure Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

12.4.5 UniQure Recent Developments

12.5 FinVector

12.5.1 FinVector Company Information

12.5.2 FinVector Business Overview

12.5.3 FinVector Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)

12.5.4 FinVector Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

12.5.5 FinVector Recent Developments

12.6 MolMed

12.6.1 MolMed Company Information

12.6.2 MolMed Business Overview

12.6.3 MolMed Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)

12.6.4 MolMed Viral Vectors and Plasmid DNA Manufacturing Product Portfolio

- 12.6.5 MolMed Recent Developments
- 12.7 MassBiologics
 - 12.7.1 MassBiologics Company Information
 - 12.7.2 MassBiologics Business Overview
 - 12.7.3 MassBiologics Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.7.4 MassBiologics Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.7.5 MassBiologics Recent Developments
- 12.8 Richter-Helm
 - 12.8.1 Richter-Helm Company Information
 - 12.8.2 Richter-Helm Business Overview
 - 12.8.3 Richter-Helm Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.8.4 Richter-Helm Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.8.5 Richter-Helm Recent Developments
- 12.9 FUJIFILM Diosynth Biotechnologies
 - 12.9.1 FUJIFILM Diosynth Biotechnologies Company Information
 - 12.9.2 FUJIFILM Diosynth Biotechnologies Business Overview
 - 12.9.3 FUJIFILM Diosynth Biotechnologies Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.9.4 FUJIFILM Diosynth Biotechnologies Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.9.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 12.10 Lonza
 - 12.10.1 Lonza Company Information
 - 12.10.2 Lonza Business Overview
 - 12.10.3 Lonza Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.10.4 Lonza Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.10.5 Lonza Recent Developments
- 12.11 Aldevron
 - 12.11.1 Aldevron Company Information
 - 12.11.2 Aldevron Business Overview
 - 12.11.3 Aldevron Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.11.4 Aldevron Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.11.5 Aldevron Recent Developments
- 12.12 Eurogentec
 - 12.12.1 Eurogentec Company Information

- 12.12.2 Eurogentec Business Overview
- 12.12.3 Eurogentec Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
- 12.12.4 Eurogentec Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
- 12.12.5 Eurogentec Recent Developments
- 12.13 Cell and Gene Therapy Catapult
 - 12.13.1 Cell and Gene Therapy Catapult Company Information
 - 12.13.2 Cell and Gene Therapy Catapult Business Overview
 - 12.13.3 Cell and Gene Therapy Catapult Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.13.4 Cell and Gene Therapy Catapult Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.13.5 Cell and Gene Therapy Catapult Recent Developments
- 12.14 Biovian
 - 12.14.1 Biovian Company Information
 - 12.14.2 Biovian Business Overview
 - 12.14.3 Biovian Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.14.4 Biovian Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.14.5 Biovian Recent Developments
- 12.15 Thermo Fisher Scientific (Brammer Bio)
 - 12.15.1 Thermo Fisher Scientific (Brammer Bio) Company Information
 - 12.15.2 Thermo Fisher Scientific (Brammer Bio) Business Overview
 - 12.15.3 Thermo Fisher Scientific (Brammer Bio) Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.15.4 Thermo Fisher Scientific (Brammer Bio) Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.15.5 Thermo Fisher Scientific (Brammer Bio) Recent Developments
- 12.16 VGXI
 - 12.16.1 VGXI Company Information
 - 12.16.2 VGXI Business Overview
 - 12.16.3 VGXI Revenue in Viral Vectors and Plasmid DNA Manufacturing Business (2019-2024)
 - 12.16.4 VGXI Viral Vectors and Plasmid DNA Manufacturing Product Portfolio
 - 12.16.5 VGXI Recent Developments
- 12.17 PlasmidFactory
 - 12.17.1 PlasmidFactory Company Information
 - 12.17.2 PlasmidFactory Business Overview
 - 12.17.3 PlasmidFactory Revenue in Viral Vectors and Plasmid DNA Manufacturing

Business (2019-2024)

12.17.4 PlasmidFactory Viral Vectors and Plasmid DNA Manufacturing Product

Portfolio

12.17.5 PlasmidFactory Recent Developments

13 REPORT CONCLUSION

14 DISCLAIMER

I would like to order

Product name: Viral Vectors and Plasmid DNA Manufacturing Industry Research Report 2024

Product link: <https://marketpublishers.com/r/VDC1C55AB35CEN.html>

Price: US\$ 2,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VDC1C55AB35CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970